Ohio State University

Running trials

• Not yet recruiting

  Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

  NCT07594548· Phase 1· Source

• Not yet recruiting

  Gestational Hypertension and Preeclampsia Blood Pressure (BP) Treatment Goals Less Than 140/90 vs. Less Than 160/110 mmHg: The GOALPOST Trial

  NCT07746271· Phase 3· Source

• Recruiting

  The Study of Chronic Obstructive Pulmonary Disease (COPD) Participants Treated With Dupilumab (STRIDE) Registry

  NCT07612878· Source

• Recruiting

  Self-Supervised Constraint-Induced Movement Therapy for Stroke Recovery

  NCT07723300· Source

• Recruiting

  A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression

  NCT07716098· Phase 3· Source

• Recruiting

  Parent-Mediated Telehealth Intervention for Insomnia in Young Autistic Children

  NCT07435740· Source

• Recruiting

  A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)

  NCT07393282· Phase 3· Source

• Recruiting

  Study of INCA036978 in Participants With Myeloproliferative Neoplasms

  NCT07441694· Phase 1· Source

• Active, not recruiting

  An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

  NCT07517263· Phase 3· Source

• Recruiting

  Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

  NCT07326566· Phase 2· Source

• Recruiting

  A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

  NCT06769698· Phase 2· Source

• Recruiting

  Safety and Efficacy of Adjunct Therapies in Adults With Type 1 Diabetes: Multicenter, Registry Study

  NCT07676565· Source

• Recruiting

  Stroke Volume-based Fluid Resuscitation in AP

  NCT07756476· Source

• Recruiting

  Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)

  NCT07224360· Phase 2· Source

• Recruiting

  Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma

  NCT07225621· Phase 2· Source

• Recruiting

  A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

  NCT07276399· Phase 3· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

  NCT06793215· Phase 3· Source

• Active, not recruiting

  Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis

  NCT07219121· Phase 4· Source

• Recruiting

  A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)

  NCT07175038· Phase 2· Source

• Recruiting

  Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

  NCT07007312· Phase 3· Source

• Active, not recruiting

  A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

  NCT07169578· Phase 3· Source

• Enrolling by invitation

  AB-1005 Long-Term Follow-up Study

  NCT07081841· Source

• Active, not recruiting

  A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)

  NCT06985147· Phase 2· Source

• Recruiting

  A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK

  NCT06990399· Phase 3· Source

• Active, not recruiting

  P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk

  NCT06468033· Phase 3· Source

• Recruiting

  Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis

  NCT06950385· Phase 3· Source

• Recruiting

  A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE

  NCT06996080· Phase 3· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease

  NCT06976216· Phase 3· Source

• Recruiting

  Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

  NCT07177352· Phase 3· Source

• Recruiting

  A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer

  NCT06533644· Phase 2· Source

• Recruiting

  Rapid Evacuation and Access of Cerebral Hemorrhage Trial

  NCT06870812· Source

• Recruiting

  Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors

  NCT07080242· Phase 1· Source

• Recruiting

  Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML/HR-MDS and in Combination With Azacitidine in Previously Untreated HR-MDS

  NCT06533761· Phase 1· Source

• Recruiting

  Lead-212 PSV359 Therapy for Patients With Solid Tumors

  NCT06710756· Phase 1/2· Source

• Recruiting

  A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)

  NCT06615050· Phase 3· Source

• Recruiting

  Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease

  NCT06529822· Phase 1· Source

• Recruiting

  Ultra-High Frequency - Electrocardiogram (UHF-ECG) for the Diagnosis of Ventricular Electrical Dyssynchrony (VED)

  NCT06641362· Source

• Recruiting

  A Randomized Study of SPK-10001 Gene Therapy in Participants With Huntington's Disease

  NCT06826612· Phase 1/2· Source

• Recruiting

  SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

  NCT06743126· Phase 3· Source

• Active, not recruiting

  Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy

  NCT06712407· Phase 4· Source

• Recruiting

  First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

  NCT06657222· Phase 1/2· Source

• Active, not recruiting

  A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT06588855· Phase 3· Source

• Recruiting

  CoMind Early Feasibility Study

  NCT06368648· Source

• Recruiting

  Diabetes RElated to Acute Pancreatitis and Its Mechanisms: Metabolic Outcomes Using Novel CGM Metrics

  NCT06401577· Source

• Recruiting

  REvascularization CHoices Among Under-Represented Groups Evaluation: The RECHARGE Trial - Minorities

  NCT06399705· Phase 3· Source

• Recruiting

  A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

  NCT06585787· Phase 3· Source

• Recruiting

  REvascularization CHoices Among Under-Represented Groups Evaluation: The RECHARGE Trial - Women

  NCT06399692· Phase 3· Source

• Recruiting

  Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC

  NCT06567743· Phase 2· Source

• Recruiting

  A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis

  NCT06559150· Phase 2· Source

• Recruiting

  SMP-3124LP in Adults With Advanced Solid Tumors

  NCT06526819· Phase 1/2· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer11 recruiting
• Head and neck cancer7 recruiting
• Acute myeloid leukemia5 recruiting
• Alzheimer disease5 recruiting
• Bladder cancer5 recruiting
• Childhood cancers4 recruiting
• Colorectal cancer4 recruiting
• Coronary artery disease4 recruiting
• Type 1 diabetes4 recruiting
• Gastric and esophageal cancer3 recruiting
• Melanoma3 recruiting
• Multiple myeloma3 recruiting
• Myelodysplastic syndromes3 recruiting
• Ovarian cancer3 recruiting
• Sarcoma3 recruiting
• Stroke3 recruiting
• Atrial fibrillation2 recruiting
• Glioblastoma2 recruiting
• High blood pressure2 recruiting
• Myeloproliferative neoplasms2 recruiting
• Neuroendocrine tumours2 recruiting
• Pancreatic cancer2 recruiting
• Parkinson disease2 recruiting
• Prostate cancer2 recruiting
• Triple-negative breast cancer2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Amyloidosis1 recruiting
• Autism1 recruiting
• Chronic kidney disease1 recruiting
• COPD1 recruiting
• Cystic fibrosis1 recruiting
• Depression1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Epilepsy1 recruiting
• Follicular lymphoma1 recruiting
• Frontotemporal dementia1 recruiting
• Heart failure1 recruiting
• Huntington's disease1 recruiting
• Kidney cancer1 recruiting
• Mantle cell lymphoma1 recruiting
• Mesothelioma1 recruiting
• Pulmonary arterial hypertension1 recruiting
• Schizophrenia1 recruiting
• Sickle cell disease1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  VOLT-AF IDE Clinical Study

  NCT06223789· Source

• Completed

  A Study of the THERMOCOOL SMARTTOUCH Surround Flow (SF) Catheter With the TRUPULSE Generator for Treatment of Drug Refractory Symptomatic PAF

  NCT06144632· Source

• Recruiting

  A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.

  NCT06022029· Phase 1· Source

• Withdrawn

  Telemonitoring to Treat Group 2 Pulmonary Hypertension

  NCT04882774· Phase 2· Source

• Terminated

  Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer

  NCT05631574· Phase 1· Source

• Completed

  Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy Bodies

  NCT05225415· Phase 2· Source

• Completed

  A 12-Week Crossover Study to Assess the Efficacy, Safety and Tolerability of L1-79 in Subjects Aged 12-21 Years With Autism Spectrum Disorder

  NCT05067582· Phase 2· Source

• Terminated

  Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease

  NCT05026177· Phase 3· Source

• Terminated

  A Trial to Evaluate the Efficacy and Safety of PQ912 in Patients With Early AD

  NCT03919162· Phase 2· Source

• Terminated

  A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)

  NCT04809467· Phase 1/2· Source

• Completed

  AB-2004 in Treatment of Irritability Associated With Autism Spectrum Disorder (ASD)

  NCT04895215· Phase 2· Source

• Completed

  Study of Liposomal Annamycin for the Treatment of Subjects with Soft-Tissue Sarcomas (STS) with Pulmonary Metastases

  NCT04887298· Phase 1/2· Source

• Terminated

  To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)

  NCT04551066· Phase 3· Source

• Completed

  Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3)

  NCT04880434· Phase 2· Source

• Completed

  A 12-Week Placebo-Controlled Study to Investigate the Efficacy, Safety, and Tolerability of RO7017773 in Participants Aged 15-45 Years With Autism Spectrum Disorder (ASD)

  NCT04299464· Phase 2· Source

• Completed

  Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC

  NCT04260126· Phase 2· Source

• Terminated

  The RECOVER sUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes

  NCT04753385· Source

• Completed

  Tailored vs. Anatomical Ablation Strategy for Persistent Atrial Fibrillation

  NCT04702451· Source

• Completed

  Trial of eRapa to Prevent Progression in Familial Adenomatous Polyposis Patients Under Active Surveillance

  NCT04230499· Phase 2· Source

• Completed

  Prospective Treatment Efficacy in IPF Using Genotype for Nac Selection (PRECISIONS) Trial

  NCT04300920· Phase 3· Source

• Completed

  Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin

  NCT04387461· Phase 2· Source

• Completed

  Improving Cardiovascular Risk Factors in Black Young Adults

  NCT04412954· Source

• Completed

  A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT)

  NCT04640077· Phase 2· Source

• Completed

  A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression

  NCT04599855· Phase 4· Source

• Completed

  Accelerating Colorectal Cancer Screening Through Implementation Science in Appalachia

  NCT04427527· Source

• Completed

  Cognitive Behavioral Therapy and Real-Time Pain Management Intervention for Sickle Cell Via Mobile Applications

  NCT04419168· Source

• Terminated

  A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)

  NCT04459715· Phase 3· Source

• Completed

  Sickle Cell Disease and CardiovAscular Risk - Red Cell Exchange Trial (SCD-CARRE)

  NCT04084080· Phase 3· Source

• Completed

  Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL

  NCT04155710· Phase 1· Source

• Completed

  Roflumilast or Azithromycin to Prevent COPD Exacerbations Trial

  NCT04069312· Phase 3· Source

• Completed

  Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD

  NCT04023552· Phase 3· Source

• Completed

  TRC-PAD Program: In-Clinic Trial-Ready Cohort

  NCT04004767· Source

• Completed

  Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced, Unresectable Pancreatic Cancer

  NCT03941093· Phase 3· Source

• Terminated

  Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

  NCT03645928· Phase 2· Source

• Completed

  Light Treatment Effectiveness (LITE) Study

  NCT03726489· Source

• Withdrawn

  The Natural History of Parkinson's Disease-associated Spinal Disorders

  NCT04101513· Source

• Completed

  Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001

  NCT02655601· Phase 1/2· Source

• Completed

  Phase 1 Study of BAY1905254 - An Early Clinical Research Study to Evaluate a New Drug Called Bapotulimab (BAY1905254) in the Expansion Cohort in Combination With Pembrolizumab in Head and Neck Cancer That Has Returned or is Discovered to be Metastatic and is Expressing PDL1.

  NCT03666273· Phase 1· Source

• Completed

  A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS

  NCT03573310· Phase 1· Source

• Completed

  Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer

  NCT03414684· Phase 2· Source

• Terminated

  WAveCrest Vs. Watchman TranssEptal LAA Closure to REduce AF-Mediated STroke 2

  NCT03302494· Phase 3· Source

• Completed

  Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas

  NCT03231306· Phase 2· Source

• Completed

  Does Cefoxitin or Piperacillin-Tazobactam Prevent Postoperative Surgical Site Infections After Pancreatoduodenectomy?

  NCT03269994· Phase 3· Source

• Terminated

  Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma

  NCT03024437· Phase 1/2· Source

• Completed

  A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer

  NCT03093922· Phase 2· Source

• Completed

  Memory Improvement Through Nicotine Dosing (MIND) Study

  NCT02720445· Phase 2· Source

• Completed

  A Collaborative Palliative and Oncology Care Model for Patients With Acute Myeloid Leukemia

  NCT02975869· Source

• Completed

  Alzheimer's Disease Neuroimaging Initiative 3

  NCT02854033· Source

• Completed

  Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer

  NCT02228681· Phase 2· Source

• Recruiting

  Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

  NCT02074839· Phase 1· Source